European Journal of Cancer
Volume 43, Issue 16 , Pages 2359-2365 , November 2007

Stem cell transplantation in Europe: Trends and prospects

  • S.S. Tan

      Affiliations

    • Erasmus MC University Medical Center, Institute for Medical Technology Assessment, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 10 4088623; fax: +31 10 4089081.
    • ,
  • C.A. Uyl-de Groot

      Affiliations

    • Erasmus MC University Medical Center, Institute for Medical Technology Assessment, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
    • VU University Medical Center, Department of Haematology, Amsterdam, The Netherlands
    • ,
  • P.C. Huijgens

      Affiliations

    • VU University Medical Center, Department of Haematology, Amsterdam, The Netherlands
    • ,
  • W.E. Fibbe

      Affiliations

    • Leiden University Medical Center, Department of Haematology, Leiden, The Netherlands

Received 5 July 2007 ,Revised 21 August 2007 ,Accepted 24 August 2007.

References 

  1. Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant. 2005;11(6):403–422
  2. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A European Group for Blood and Marrow Transplantation (EBMT), Joint Accreditation Committee, International Society for Cellular Therapy. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37(12):1069–1085
  3. Gratwohl A European Group for Bone Marrow Transplantation (EBMT). Bone marrow transplantation activity in Europe 1990. Bone Marrow Transplant. 1991;8(3):197–201
  4. Lokhorst H Myeloomwerkgroep van de stichting Hemato-oncologie voor Volwassenen Nederland. De moderne behandeling van het multipel myeloom: een richtlijn van de stichting Hemato-oncologie voor Volwassenen Nederland (HOVON). Ned Tijdschr Geneeskd. 2005;149(15):808–813
  5. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439–449
  6. Rowe J, Buck G, Burnett AK, et al. ECOG MRC/NCRI Adult Leukemia Working Party Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767
  7. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086
  8. Breems D, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol. 2005;130(6):825–833
  9. Suciu S, Mandelli F, de Witte T, et al. EORTC and GIMEMA Leukemia Groups Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232–1240
  10. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ‘what is the best recipe?’. Bone Marrow Transplant. 2005;36(7):565–574
  11. Lima MD, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol. 2006;43(2):107–117
  12. Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005;11(2):85–92
  13. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005;23(26):6316–6324
  14. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23(30):7583–7593
  15. Jost LM, Kloke O, Stahel RA ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma. Ann Oncol. 2005;16(Suppl 1):i58–i59
  16. Federico M, Bellei M, Brice P, et al. EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21(12):2320–2325
  17. Oscier D, Fegan C, Hillmen P, et al. Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125(3):294–317
  18. Faber L. Behandeling van het indolent non-Hogkin lymfoom: een richtlijn van de Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON). Amsterdam: HOVON; 2005;
  19. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35(10):943–951
  20. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941
  21. Harrouseau JL, Greil R, Kloke O ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16(Suppl. 1):i45–i47
  22. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(9):649–658
  23. de Giorgi U, Rosti G, Papiani G, Marangolo M. The status of high dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor. Haematologica. 2002;87:95–104
  24. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. New Engl J Med. 2003;349(1):7–16
  25. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003;40(5):276–287
  26. van Steekelenburg M, van Weel-Sipman MH, Zwinderman AH, Hoogerbrugge PM, Vossen JM, Egeler RM. Favorable current prognosis after HLA-identical bone marrow transplantation for children with required severe aplastic anemia; evaluation of 30 years of bone marrow transplantation at the Leiden University Medical Center. Ned Tijdschr Geneeskd. 2002;146(33):1542–1546
  27. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol. 2006;13(3):142–148
  28. Samijn JP, te Boekhorst PA, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatr. 2006;77(1):46–50
  29. Traynor AE, Barr WG, Rosa RM, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002;46(11):2917–2923
  30. Tan SS, Uyl-de Groot CA, Huijgens PC, Fibbe WE, Cornelissen JJ. Ontwikkelingen stamceltransplantaties en het pakket (report no. 06.80). Rotterdam: Institute for Medical Technology Assessment; 2006;

PII: S0959-8049(07)00691-0

doi: 10.1016/j.ejca.2007.08.020

European Journal of Cancer
Volume 43, Issue 16 , Pages 2359-2365 , November 2007

Article Tools

* Image Usage & Resolution